MK-677

Intro

MK-677 (ibutamoren mesylate) is a non-peptide, orally bioavailable ghrelin receptor agonist developed by Merck in the 1990s as a potential pharmaceutical treatment for growth hormone deficiency.

Its defining feature is oral GH elevation — a capability effectively unique to this compound among commercially available secretagogues. No injections, no cold storage, no reconstitution.

The compound mimics ghrelin at the GHS-R1a receptor in the pituitary gland, amplifying the amplitude of each existing GH pulse rather than adding new ones, producing approximately 12 stronger-than-normal pulses over 24 hours. The liver responds with sustained IGF-1 production across the full daily cycle — fundamentally different from injectable GH secretagogues, which produce brief pulsatile spikes that resolve within minutes to hours.

Merck ran multiple clinical trials across aging, obesity, hip fracture recovery, and Alzheimer's disease. In every trial, GH and IGF-1 improved reliably. Patient outcomes in the disease indications tested did not meet approval thresholds. One trial was stopped early over a possible cardiovascular signal. Without a pharmaceutical champion, the compound migrated to the gray market where it has been available as a research chemical for roughly two decades.

The landmark two-year Nass/Thorner RCT (n=65, ages 60–81, 25mg/day) confirmed daily MK-677 restores GH and IGF-1 to young-adult range — 97% increase in mean 24-hour GH concentration, 55% increase in IGF-1. It does not suppress endogenous GH or testosterone production. No post-cycle therapy is required. Gains are maintainable post-cycle because they do not depend on supraphysiological androgen levels.

The primary liability is metabolic. Elevated GH liberates free fatty acids from adipose tissue, which inhibit IRS-1 → GLUT-4 insulin signaling, elevating serum glucose. This insulin resistance is dose-dependent and progressive. Blood glucose monitoring with a home glucometer is mandatory at every dose level — it is not optional.

Observed Effects

The most reliable and fastest-onset benefit is sleep quality improvement: deeper architecture, highly vivid or cinematic dreams, the ability to feel rested on fewer hours, improved morning readiness.

Onset within one to two weeks at any standard dose. Human studies document REM sleep improvement of 20–50%.

IGF-1 elevation is the most objectively documentable effect. First-person bloodwork shows IGF-1 rising from 140 ng/mL to approximately 290 ng/mL on 20mg/day over six months — consistent with clinical trial data (55% increase at 25mg/day). Functional equivalence to 3–8 IU/day of pharmaceutical-grade GH observed across multiple individuals' bloodwork by practitioners.

Muscle accumulation is real but gradual. A two-month RCT in 24 obese men at 25mg/day showed +3 kg lean mass versus placebo by DEXA scan with no change in total body fat — body recomposition at 8 weeks. Community logs at 12.5mg/day over 12 weeks show approximately +5 kg total (predominantly lean with some water), rate slowing after week 8. Compared head-to-head with injectable HGH, MK-677 muscle growth is slower and carries more water retention.

Hair, nail, and skin improvements emerge reliably at weeks 3–4 across dose ranges of 10–35mg/day. In elderly users (70s), two-year continuous use documented resolution of arthritis in the knuckles and body fat reduction.

MK-677 produces all five GH isoforms (22kDa, 20kDa, 17kDa, 15kDa, and heterodimers) versus injectable HGH's single 22kDa form — specifically cited by practitioners as advantageous for recovery and repair contexts.

At higher doses, sustained nitrogen retention creates what practitioners describe as feeling 'like you just got out of the gym' throughout the day — intramuscular glycogen loading and anabolic milieu maintained continuously. This is mechanistically distinct from subcutaneous water retention bloat.

Bone mineralization is documented in clinical studies. Bone turnover markers (both resorption and formation) increase simultaneously — coupled remodeling consistent with GH-IGF-1 axis stimulation, not net resorption.

Field Reports

Sleep quality improvement is the experience that anchors MK-677's community reputation. It arrives within one to two weeks, and in those who respond, produces a qualitatively distinct experience: deeper, more architecturally complete sleep with vivid or cinematic dreams, the ability to feel restored on fewer hours, and improved morning readiness. This effect is why many users skeptical of body composition claims continue MK-677 primarily as a sleep intervention.

The approximately half of users for whom MK-677 disrupts rather than improves sleep represent a significant community blind spot. The nighttime hunger mechanism — ghrelin receptor activation driving appetite surges during the sleep window — wakes these users or prevents deep sleep onset. Practitioners with broad client exposure flag this as 'near 50/50.' Users experiencing nighttime hunger-disrupted sleep typically respond to: earlier evening dosing and tightly limiting food volume at the final meal.

Water retention is universally experienced at mid-cycle and is the dominant complaint across all dose levels. Bloating around the midsection and face masks lean mass accrual that DEXA scanning confirms is occurring underneath. Some users track tape measurements rather than mirror aesthetics during the cycle to separate the two effects.

The hunger response is highly individual. Some users find appetite stimulation overwhelming from day one; others report no meaningful hunger effect at 30mg/day. A third group experiences intense early hunger that attenuates substantially after 2–4 weeks as ghrelin receptor accommodation occurs. The variance is large enough that individual appetite response cannot be predicted in advance.

In head-to-head comparisons against injectable HGH by users who have run both: MK-677 produces real but slower lean mass accrual, significantly more water retention, and an IGF-1 plateau that injectable HGH at comparable cost can exceed. Community bloodwork documentation: IGF-1 from 140 to approximately 290 ng/mL on 20mg/day over six months — a meaningful elevation. A 12-week log at 12.5mg/day documented body weight progression from 76kg to 81kg, predominantly lean mass with some water, rate of gain slowing after week 8.

Hair and nail growth acceleration is the most visible and pleasant cosmetic effect — documented consistently across dose ranges starting at weeks 3–4, alongside skin quality improvement. These are reliable markers that the compound is biologically active.

Blood glucose management practices documented in community logs: berberine + chromium picolinate + cinnamon bark as the standard protective combination; some users avoid checking daily (not recommended); those who do check report occasional low readings when combining blood glucose interventions with low-carbohydrate diets.

Community Consensus

MK-677 occupies a unique position: it has more human clinical trial data than almost any comparable unapproved GH-secretagogue compound, a clear and well-characterized mechanism, oral convenience that no other GH secretagogue matches, and a cost structure that makes injectable HGH comparisons central to community discussion, yet it has never received FDA approval and remains in legal gray territory.

The defining community debate is MK-677 versus injectable HGH. The consensus is not that one is objectively better; it is that MK-677 offers oral convenience and lower cost at the expense of ceiling potency, appetite stimulation, water retention, and glucose drift.

The SARM misclassification is persistent. Consumer channels often place MK-677 next to SARMs, so buyers assume the mechanism is similar. It is not: MK-677 acts on the ghrelin receptor, has no androgen receptor activity, does not suppress testosterone, and requires no SARM-style PCT.

Merck's abandonment despite robust clinical hormone-marker data is the background narrative explaining the gray-market afterlife. The compound improved GH/IGF-1 markers in trials, but patient outcomes in specific disease indications did not meet approval thresholds.

A concerning use pattern is adolescent heightmaxxing. Reports of minors using MK-677 before growth-plate closure should be treated as a hard warning case: brain-development, anxiety, sleep, joint-pain, and escalation risks are not adequately understood. Under-25 use should remain a red flag rather than a curiosity lane.

Risks & Monitoring

Insulin resistance and blood glucose elevation is the primary safety concern. Elevated GH liberates free fatty acids → IRS-1 inhibition → GLUT-4 cannot translocate → serum glucose rises.

Dose-dependent and progressive. Blood glucose monitoring with a home glucometer is non-negotiable — even for oral-only protocols. Community glucose targets: 70–85 mg/dL ideal; 85–89 healthy; 90–100 acceptable; 100–125 at-risk; 126+ diabetes threshold requiring immediate discontinuation. Consistent readings above 100 mg/dL is the standard discontinuation trigger.

Water retention is the most universally reported complaint — manifests as mid-cycle bloating around midsection and face, masking muscle definition gains. Dose-proportional and most pronounced above 20mg/day. Critical: conventional diuretics (furosemide, hydrochlorothiazide) must NOT be used to manage GH-class water retention — documented risk of sudden death via hypokalemia and cardiac arrhythmia. Natural diuretics (increased water intake 1.5–2 gallons/day, dandelion root 500–4,000mg/day) provide mild relief safely.

Sleep disruption affects approximately half of users despite the compound's reputation as a sleep enhancer. The mechanism is nighttime ghrelin receptor activation driving hunger surges that wake users or prevent sleep onset. Practitioners with broad client exposure characterize the sleep outcome as 'near 50/50.' High food volume in the evening compounds this — food volume management is required to preserve sleep quality.

Daytime lethargy is common mid-to-late cycle, attributed to post-dose GH somnolence. Shifting to evening dosing converts this from daytime impairment to sleep-enhancing effect.

Tingly fingers and hands — carpal-tunnel-like paresthesia from fluid accumulation compressing the carpal tunnel. Classic GH-class side effect, dose-dependent, resolves on cessation.

Appetite dysregulation is highly variable: some users find hunger overwhelming from day one; others report no meaningful hunger effect at standard doses; some experience intense hunger that attenuates significantly at 2–4 weeks as ghrelin receptor accommodation occurs.

Prolactin-mediated gynecomastia has been documented in younger users above 20mg/day. Mechanism: ghrelin receptor activation → prolactin elevation (not estrogen). Aromatase inhibitors are ineffective — the correct intervention is P5P (pyridoxal-5-phosphate, active B6 form) preventively; Cabergoline or Pramipexole for escalation. At 20mg/day and below, prolactin gyno is described as 'extremely unlikely.'

HPT axis effects: evidence suggests MK-677 may lower serum testosterone and estrogen at higher doses via prolactin feedback. Flagged as monitoring concern for longer cycles above 20mg/day.

Under-25 use carries a distinct permanent risk: use before age 25 is documented to permanently alter brain chemistry, predisposing users to PTSD, anxiety, and sleep disorders persisting after discontinuation — via GH-axis effects during neural development. The potential height gain (estimated ~1 inch) does not justify this risk.

Joint pain in adolescents: severe knee and ankle pain documented at 20mg/day in adolescent users — counterintuitive given MK-677's adult joint repair reputation. Mechanism: rapid tissue expansion creating joint pressure in an immature skeletal system, or water retention-related joint swelling.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Injury recovery and post-surgery: The strongest practitioner-level rationale for MK-677. The multi-isoform GH output (all five GH isoforms versus injectable HGH's single 22kDa form) is specifically preferred in recovery contexts. Standard recovery protocol: MK-677 10–25mg + TB-500 + BPC-157 + high vitamin C intake + collagen-rich diet. Post-surgical limited mobility naturally reduces the insulin resistance burden from GH elevation, making this a particularly well-tolerated application. Eight to twelve weeks minimum is required for meaningful connective tissue benefit — collagen synthesis timelines require sustained IGF-1 elevation.

Injection-averse users: MK-677 is effectively the only viable oral GH-axis intervention. The trade-off versus injectable protocols is explicit: slower lean mass accrual, more water retention, and a hard ceiling that injectable alternatives can exceed. But for users who will not inject under any circumstances, MK-677 provides genuine and documented GH-axis benefits.

Elderly or declining GH output (60s+): Clinical trial evidence specifically supports this population. The Thorner/Nass 2-year RCT was conducted in adults ages 60–81. Documented benefits include FFM preservation, reversal of sarcopenia markers, and possible bone mineralization. However, experienced practitioners note this population is also most prone to side effects (edema, blood sugar dysfunction, persistent hunger), and many prefer injectable Ipamorelin + CJC-1295 for injection-willing elderly patients. MK-677 is reserved for the truly injection-averse elderly.

Mass/bulking off-season: 25–30mg before bed, accepting the full appetite drive and water retention as protocol features rather than liabilities. Requires comprehensive insulin sensitizer support and consistent glucose monitoring. Water retention to be managed during a subsequent cut phase.

Cost-conscious lean phase / recomposition: 10–20mg before bed, five days on / two days off. Expect gradual lean mass accrual over 12+ weeks without the metabolic cost of higher doses. Most sustainable approach for long-duration protocols.

Weekday GH / Weekend MK-677 periodization (advanced): Exogenous GH Monday through Friday (0.25 IU before bed) addresses thymic and longevity cascades; MK-677 0.5–1mg on weekends restores the enzymatic GH production cascade — making the following week's exogenous GH work more effectively. Requires exogenous GH access; not beginner-appropriate.

Dosing Details

Community practice has converged on three functional dose tiers that reflect the blood-glucose cost-benefit tradeoff: lower 10 mg/day-style optimization use, intermediate 15 mg/day threshold use, and 25 mg/day clinical-trial-style exposure. Higher exposure raises insulin-resistance, edema, hunger, and prolactin concerns. Longevity-oriented reports also discuss 1-5 mg/day or even sub-milligram use, but those low-dose lanes are less clinically anchored.

Timing reports usually favor evening or fasted windows to align with nocturnal GH biology, while high-carbohydrate or cheat-day use is often avoided because post-meal somatostatin can blunt secretagogue effects and the glucose burden is already elevated. Sublingual and swallowed oral use both appear in community practice.

Cycling reports include two-weeks-on/one-week-off or five-days-on/two-days-off patterns to manage insulin sensitivity. MK-677 does not require SARM-style PCT because it is not an androgen and does not shut down testosterone. Discontinuation thresholds in reports center on persistent fasting-glucose elevation, prolactin symptoms, gynecomastia symptoms, and sleep deterioration.

Stacks & Alternatives

Overlapping GH-axis escalation, not a default stack. CJC-1295/ipamorelin is usually the cleaner injectable GH-secretagogue route; MK-677 is usually the oral/injection-averse alternative. Combining them can raise total GH/IGF-1 pressure but also compounds fasting-glucose elevation, edema, appetite drive, and water retention. Reserve discussion for advanced growth-phase use with baseline glucose/A1c and IGF-1 monitoring; do not present it as foundational for recomp, fat loss, or lean-looking muscle gain.

Community-standard insulin sensitizer harm-reduction stack. Berberine (500mg twice daily) is the primary agent — activates AMPK and improves insulin sensitivity comparably to Metformin. Chromium picolinate enhances glucose disposal. Cinnamon bark has mild insulin-mimetic properties. This triple combination is the most consistently cited protective stack across community experience logs.

Full insulin sensitizer protocol for higher-dose MK-677 use. L-carnitine L-tartrate (500mg per meal, 2,000–3,000mg/day) shuttles fatty acids into mitochondria, reducing the circulating free fatty acid burden driving GH-induced insulin resistance. Omega-3 (800mg EPA+DHA per meal) independently improves insulin sensitivity. Magnesium bisglycinate (100–200mg per meal) addresses the magnesium cofactor requirement — GHS-R1a receptor activation is acutely dependent on magnesium ion availability.

Injury and recovery stack. MK-677's multi-isoform GH output is specifically preferred in recovery contexts; TB-500 provides systemic tissue repair and anti-inflammatory signaling; BPC-157 accelerates local healing of connective tissue, tendons, and joints. Complete recovery protocol adds high vitamin C intake and collagen-rich diet.

Somatostatin-blunting amino acid protocol to maximize GH pulse amplitude. Arginine (5,000–10,000mg) is the primary somatostatin antagonist; ornithine (2,000–10,000mg) and lysine (1,000–3,000mg) are synergistic. Taken before bed to reduce somatostatin levels during the nocturnal GH pulse window, allowing higher GH output even in a semi-fed state.

Appetite adjunct for aggressive mass protocols. GHRP-6 (300mcg) used as a targeted final-meal appetite amplifier when MK-677's hunger drive is waning later in the day. Both compounds target the same ghrelin receptor — additive effect on appetite when timed to the final meal before the extended fasting window before bedtime dosing.

Alternatives

Stack Cost

Practical Setup

Blood glucose monitoring is the central practical requirement and cannot be treated as optional.

A home glucometer and test strips are required equipment at every dose level. Glucose intervention ladder in escalating order: Berberine 500–2,000mg daily → Metformin 500–1,500mg daily → GLP-1 agonist at micro-dose → SGLT-2 inhibitor (Canagliflozin 100mg/day) → DPP-4 inhibitor (Sitagliptin 100mg/day) → dose reduction → discontinuation. Target fasting glucose below 89 mg/dL when interventions are deployed.

No cold storage or reconstitution. Stores at room temperature in liquid or capsule form. Meaningful practical advantage over injectable GH protocols.

No PCT, no testosterone suppression, no androgenic effects. MK-677 does not interact with the androgen receptor, does not suppress testosterone, and does not cause or accelerate male pattern baldness. Any hair loss on MK-677 would be temporary shedding, not androgenic progression. Gains are maintainable post-cycle because they are not dependent on supraphysiological androgen levels.

The pituitary ceiling is a hard pharmacological limit. MK-677 amplifies GH pulses but cannot produce more GH than the pituitary is capable of releasing. Users over 30 hit this ceiling faster as natural GH production capacity declines. No dose above 25mg/day provides additional IGF-1 benefit — the pituitary's maximum pulse amplitude is the bottleneck, not the compound's dose.

Prolactin monitoring above 20mg/day. P5P (pyridoxal-5-phosphate, active form of vitamin B6) preventively reduces prolactin-mediated gyno risk. If gynecomastia symptoms develop: Cabergoline or Pramipexole escalation — not aromatase inhibitors, which target estrogen rather than prolactin.

Skip on cheat days and high-carbohydrate days. Elevated post-meal somatostatin directly antagonizes MK-677's GH-releasing effect while worsening glucose burden. Six-day dosing (or five-day with weekend off) is the practical implementation.

SARM-specific information does not apply. MK-677 has no androgen receptor activity. SARM-category PCT recommendations, suppression concerns, and cycling protocols from marketing material are irrelevant to this compound.

Legal status: US research chemical, gray-market. Not a controlled substance. Banned by WADA for competitive sports. Potentially available via compounding pharmacy from clinics prescribing it off-label.

Anti-doping note: MK-677's non-22kDa GH isoform enrichment in the immediate post-dose period may produce a detectable isoform signature on WADA's GH isoform ratio detection test. Competitive athletes subject to testing should treat this as a flagged compound.

Mechanism Deep Dive

MK-677's pharmacology is defined by its spiroindoline sulfonamide chemistry — a non-peptide small molecule architecture achieving approximately 60% oral bioavailability by bypassing peptide-bond degradation that prevents injectable GH secretagogues from surviving oral administration. Half-life is approximately 5 hours, but downstream IGF-1 elevation persists across the full 24-hour cycle via the liver's sustained IGF-1 synthesis response to GH signaling.

GHS-R1a receptor activation: MK-677 binds and activates the growth hormone secretagogue receptor 1a — the same receptor that endogenous ghrelin activates. This activation amplifies the amplitude of each existing pituitary GH pulse rather than adding new ones, producing approximately 12 stronger-than-baseline pulses over 24 hours. The resulting 24-hour sustained IGF-1 elevation (40–90% above baseline) is mechanistically distinct from all injectable GH secretagogues, which produce transient IGF-1 spikes tied to their short half-lives.

Multi-isoform GH output: MK-677's pituitary stimulation produces all five physiologically active GH isoforms — 22kDa, 20kDa, 17kDa, 15kDa, and heterodimers. Pharmaceutical injectable HGH delivers only the recombinant 22kDa form. The non-22kDa proportion is highest immediately after initial MK-677 administration and normalizes over 2–8 weeks of continuous use — suggesting pituitary adaptation. Multiple isoforms have distinct receptor binding properties; this isoform diversity is cited as a rationale for MK-677's recovery advantages over single-isoform exogenous HGH. Following years of daily exogenous GH, all non-22kDa isoforms recover within 24–36 hours of cessation — the pituitary's diverse GH production capacity is not permanently suppressed.

The insulin resistance cascade: Elevated GH stimulates lipolysis in adipose tissue, releasing free fatty acids into circulation. These free fatty acids inhibit insulin receptor substrate-1 (IRS-1), preventing GLUT-4 glucose transporter translocation to cell membranes — the mechanism that normally allows cells to take up glucose from blood. Serum glucose rises because cells cannot absorb it despite adequate or elevated insulin. This process is dose-dependent, progressive over weeks, and the primary reason blood glucose monitoring is mandatory.

Somatostatin antagonism: Somatostatin (GHIH) is released from the intestinal tract and stomach in response to eating, and independently from the brain in response to elevated serum GH — a negative feedback loop that directly antagonizes all GH secretagogue effects. Somatostatin cannot be fully pharmacologically bypassed: fasting reduces GI somatostatin, but the brain's regulatory somatostatin feedback remains active and modulates the peak achievable GH pulse amplitude. Somatostatin also inhibits thyroid-stimulating hormone release, meaning somatostatin suppression protocols have broader endocrine implications. Bedtime fasted-state dosing exists specifically to minimize GI somatostatin during the nocturnal GH pulsatility window.

GHS-R1a pleiotropic effects: The ghrelin receptor is not GH-specific. Activation simultaneously modulates glucose and lipid metabolism, regulates gastrointestinal motility and gastric juice secretion, protects neuronal and cardiovascular cells, and influences immune regulation. This explains why MK-677's side effect profile includes GI effects, appetite dysregulation, and cardiovascular considerations beyond simple GH elevation.

Enzymatic pathway framing: One practitioner framework positions MK-677 as acting on the somatotropic enzyme cascade — the signaling chain between hypothalamic stimulus and target tissue — rather than binding to the receptor directly as peptide GHRPs do. This framing explains why sub-milligram micro-doses (0.5–1mg) can have meaningful effects on the enzymatic GH production system without triggering full appetite stimulation, and why MK-677 combines synergistically with receptor-binding peptides (Ipamorelin, CJC-1295) rather than competing with them.

No desensitization: Unlike injectable GHRPs (which require cycling to prevent pituitary receptor downregulation), MK-677 does not produce meaningful pituitary desensitization over extended use. Practitioners have documented sustained GH response over 12+ months, with some clients on sub-25mg protocols continuously for two to three years without loss of efficacy.

Evidence Index